ePrints

An overview of insulin glargine

Lookup NU author(s): Emeritus Professor Philip Home, Dr Simon Ashwell

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Accordingly, it mimics more closely the natural physiological profile of basal endogenous insulin secretion than do traditional extended-acting insulins such as NPH insulin. As would be expected for a more satisfactory basal insulin, clinical trials comparing insulin glargine with NPH insulin show less nocturnal hypoglycaemia, improved pre-breakfast blood glucose levels, or both. Furthermore, no substantive safety concerns have emerged for insulin glargine. Thus, insulin glargine represents the first major advance in the provision of basal insulin injection therapy for people with type 1 and type 2 diabetes for over 50 years. Copyright © 2002 John Wiley & Sons, Ltd.

Publication metadata

Author(s): Home PD; Ashwell SG

Publication type: Article

Publication status: Published

Journal: Diabetes/Metabolism Research and Reviews

Year: 2002

Volume: 18

Issue: 3

Pages: S57-S63

ISSN (print): 1520-7552

ISSN (electronic): 1520-7560

Publisher: John Wiley & Sons Ltd.

URL: http://dx.doi.org/10.1002/dmrr.317

DOI: 10.1002/dmrr.317

PubMed id: 12324987

Altmetrics

Share